touchCONGRESS

Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

Access to this content is not permitted for healthcare professionals based in the US.

Back to Home

Could not verify Country/IP Address

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Home

This activity is funded by an independent medical education grant from GSK.
This activity is funded by an independent medical education grant from GSK.
Multiple Myeloma Watch Time: 64 mins

touchCONGRESS Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

Watch this two-part activity exploring recent data for BCMA-targeting agents in multiple myeloma. Filmed following the European Hematology Association 2021 Virtual Congress.

Part 1: Watch multiple myeloma expert Dr María-Victoria Mateos review key data from the EHA2021 Virtual Congress Watch Now
Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

 

  • Part 1: Data Review
Next Chapter
Introduction
BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma
BCMA-targeting antibody–drug conjugates in relapsed/refractory multiple myeloma
BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma
Video Player Controls:
 
Leave Feedback
  • Part 2: Expert Interviews
Leave Feedback
Dr María-Victoria Mateos
Watch Time: 08:57 University of Salamanca, Salamanca, Spain

María-Victoria Mateos considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.
 
 
Leave Feedback
Dr Heather Sutherland
Watch Time: 15:28 Vancouver General Hospital, Vancouver, BC, Canada

Heather Sutherland considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.
 
Leave Feedback
Prof. Dr. Niels van de Donk
Watch Time: 14:13 Amsterdam University Medical Center, Amsterdam, The Netherlands

Niels van de Donk considers the latest data on BCMA-targeting agents for the management of relapsed/refractory multiple myeloma from the EHA2021 Virtual Congress.
 
 
Leave Feedback
Please Select A Video:
Dr María-Victoria Mateos
 University of Salamanca, Salamanca, Spain Watch Time: 08:57 Translations available:
Watch Video
Dr Heather Sutherland
 Vancouver General Hospital, Vancouver, BC, Canada Watch Time: 15:28 Translations available:
Watch Video
Prof. Dr. Niels van de Donk
 Amsterdam University Medical Center, Amsterdam, The Netherlands Watch Time: 14:13 Translations available:
Watch Video
Leave Feedback
Overview & Learning Objectives
Overview

Stay up to date with the latest data for BCMA-targeting agents in the treatment of multiple myeloma in this two-part activity. Filmed following the EHA2021 Virtual Congress.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall efficacy data for BCMA-targeting agents in the treatment of multiple myeloma
  • Describe the safety data for BCMA-targeting agents in the treatment of multiple myeloma
  • Discuss how the latest data on BCMA-targeting agents may affect the management of patients with multiple myeloma
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from GlaxoSmithKline.
This activity is provided by touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals.

Launch date: 12 July 2021.

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Feedback

Thank you for your feedback.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup